Osteosarcoma (OSA) is the most common bone tumor affecting the dog. The veterinary options for therapeutic management of OSA are limited and prognosis for such patients is poor. Oncolytic adenoviruses are attractive tools for experimental therapeutics as they can replicate and spread within tumors to directly induce tumor destruction. However, a major impediment to systemic oncolytic adenoviruses injection is the presence of pre-existing neutralizing antibodies (Nabs). In this study, we investigated the effect of a replication-selective canine adenovirus (OCCAV) to treat OSA in the presence of Nabs and the use of canine OSA cells as carrier vehicles for evading Nabs. Our systemic biodistribution data indicated that canine tumor cells could successfully reach the tumor site and deliver OCCAV to tumor cells in an immunized mice model. Furthermore, the use of carrier cells also reduced adenovirus uptake by the liver. Importantly, OCCAV alone was not effective to control tumor growth in a pre-immunized xenograft mouse model. On the contrary, systemic antitumoral activity of carrier-cell OCCAV was evident even in the presence of circulating antibodies, which is a relevant result from a clinical point of view. These findings are of direct translational relevance for the future design of canine clinical trials.
Introduction
Osteosarcoma (OSA) is the most common bone tumor affecting the dog, with approximately 8000 new cases diagnosed annually. Despite refinements to conventional therapy, the prognosis of dogs with OSA remains poor. In addition, current treatment strategies that combine radical surgery and chemotherapy often do not avoid the development of fatal distant metastatic disease within 2 years of diagnosis and treatment. 1 Thus, it is desirable to develop more effective therapies, which may slow or delay the onset of metastatic disease. Both metastatic and local diseases have been extensively characterized and are strikingly similar to their human counterpart. 2 Thus, canine OSA represents the best-characterized spontaneous animal model for human malignant disease.
Oncolytic viruses (OVs) constitute an attractive experimental therapeutic as they can potentially replicate and spread within tumors to directly induce tumor destruction or potentiate an antitumor immune response. 3 Recently, an oncolytic adenovirus serotype 5-based vector was approved for cancer therapy in human beings for the first time. 4 Hemminki et al. 5 have described the construction and characterization of a replication-competent canine adenovirus termed OCCAV. The osteocalcin promoter of OCCAV restricts the expression of the E1A protein of a canine adenovirus type 2 (CAV2) to dog OSA cells. This virus effectively replicates in and causes oncolysis of canine OSA cells in vitro as efficiently as the wild-type CAV2, but not in other canine neoplastic cells. Besides, OCCAV yielded a therapeutic benefit in vivo in a syngeneic mouse model. In a toxicology study in normal dogs where short-term physiologic indicators of stress and shockas well as gross and histological changes in a variety of tissues-were examined, no major signs of virus-associated toxicity were noted. In addition, short-term immune suppression did not increase OCCAV toxicity. 6 However, delivering an OV to tumor cells through the circulatory system is a unique challenge. Virus particles injected into the bloodstream are vulnerable to inactivation by complement proteins, are uptaken by the reticuloendothelial system, are bound to red blood cells and neutralized by circulating antibodies. 7 Among these, host antibodies are likely to be the most restrictive barrier to therapy, as they mediate a long-lasting state of immunity to repeated infections. 8 Several widely differing approaches aimed to protect circulating viral particles in the bloodstream to enhance tumor delivery are currently the focus of intense research. 9 Treatment with PEGylation, liposome encapsulation, cyclophosphamide or etoposide decreases the titer of neutralizing antibodies (Nabs) against adenoviruses and yield partial recovery of adenoviral infectivity in target cells upon a second injection. However, such modifications were ineffective in the case of third or later injections, owing to an increase in anti-adenovirus antibody titer, and, therefore, could not produce significant antitumor effects. 10 Almost all dogs have circulating anti-CAV antibodies and T-lymphocytes developed as a result of immunization or natural infection. Two serotypes of CAV have been described in dogs: CAV1 and CAV2. CAV1 is responsible for infectious canine hepatitis, whereas CAV2 generally leads only to mild infection of the upper respiratory tract. A very effective live vaccine based on serotype 2 is in routine use worldwide for the vaccination of dogs against both serotypes, with an excellent safety record. 11 In this regard, the dog population resembles the human population, which has almost universal immunity against the most commonly used human adenovirus serotypes 2 and 5.
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A promising novel way to overcome the antibody limitation is the use of cells as OV delivery vehicles. This system offers a number of potential advantages. First, certain cancer cells have tissue-homing capacity. 13, 14 Second, carrier cells can act as local virus factories allowing amplification of the inoculated virus. 15 Moreover, the OV harbored by carrier cells remains at least partly protected from the inactivation by the host until released at their destination. 16 Preclinical studies have shown that different carrier-cell types, including T cells, monocytes, endothelial cells and tumor cells (autologous, allo-or xenogenic), can prevent systemic viral elimination. 9 The idea of using tumor cells as carriers to deliver a replicative virus was first demonstrated in a regional delivery of replication-selective HSV-1 for the intraperitoneal therapy of epithelial ovarian cancer xenografts. 17, 18 Later studies, using a model of spontaneous metastases of human breast cancer, showed that intravenously (i.v.) injected tumor cells homed in metastatic lesions and were able to deliver OVs to the metastases with only localized and negligible systemic toxicity. 18, 19 Moreover, in an immunocompetent model, tumor carrier cells loaded with adenovirus generated anti-adenovirus and antitumoral cytotoxic T-lymphocytes, the activity of which could be further enhanced by granulocyte-macrophage colony-stimulating factor expression. 10 In this study, we explored the potential of using canine tumor cells as carriers for delivery of oncolytic canine adenovirus to tumor sites in a xenograft animal model. We investigated the suitability of canine OSA cells as a carrier system for the delivery of OCCAV in a xenograft animal model. We report that infected tumor cells could efficiently deliver OCCAV to the tumor site in the presence of neutralizing titers of anti-CAV antibodies, as efficiently as in the absence of pre-existing antibodies. In addition, carrier-cell-mediated delivery of the OV resulted in an enhanced therapeutic efficacy compared with the administration of the naked virion. Altogether, our findings provide evidence that supports carrier-cellmediated delivery of OV as a promising tool in the treatment of OSA in dogs. Carrier cells to elude adenoviral Nabs F Alcayaga-Miranda et al ment. Serum samples (in triplicates) were diluted twofold across a 96-well plate in Dulbecco's modified Eagle's medium 5% fetal bovine serum. One row contained no serum samples to observe the effect of virus only (positive control) and one row contained no virus infection (negative control). Dilutions of seras were incubated with 1 Â 10 4 TU per well of AdTL for 1 h at room temperature. After 1 h of incubation, 50 000 HEK293 cells per well were added to the serum-virus mixtures. Twenty-four hours after infection, the Nab titer was determined by the highest dilution, which was 50% of infection inhibition. 6 cells of AdTL-infected D17 carrier cells per mouse (in 200 ml PBS) were administered through tail vein. D17 cells were infected and irradiated as described below. Three days after injection, animals were killed with CO 2 and organs/tissues were sectioned and snap frozen. Biodistribution analysis was performed as previously described. 23 Briefly, frozen tissues were ground to a fine powder using a pestle and mortar and processed according to manufacturer instructions (Promega, Madison, WI). Luciferase enzyme activity in supernatants was assessed using luciferase assay reagent (Promega) and normalized to total protein content. The results are shown in relative light units (mg protein). Statistical significance was determined by Mann-Whitney test (Po0.05). For GFP visualization, livers and lung were processed as described previously. 20 Sections were mounted and GFP expression was viewed at Â 40 with a fluorescence microscope (Olympus BX60; Olympus America, Melville, NY) and imported into Spot Advanced imaging software (Diagnostic Instruments, Sterling Heights, MI). 6 cells per mouse (in 200 ml PBS) were given as a single injection by tail vein. To evaluate systemic efficacy in CAV2-immunized mice, the immunization was generated by a single intraperitoneal injection of OCCAV (2.5 Â 10 10 v.p. per mouse in 200 ml) 13 days before carrier cells were administered. Tumor size, as well as mice status, was recorded three times weekly, and tumor volume was calculated according to the equation
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, where W and L are the width and the length of the tumor, respectively. The percentage of growth was defined as [(V-V0)/V0] Â 100, where V0 is the tumor volume at day 0. The significance of differences in tumor growth rate between treatment groups was assessed by a two-tailed Student's unpaired t-test. The statistical significance was set at Po0.05. Intratumoral adenovirus immunofluorescence in Balb/c nu/nu tumors was performed as previously described. 22 Briefly, OCT-embedded sections from Abrams tumors obtained at day 15 after virus administration were treated with polyclonal antiadenovirus (clone Ab6982; Abcam Ltd, Cambridge, UK) and Alexa Fluor 488-labeled goat anti-rabbit (Molecular Probes, Eugene, OR) antibodies, and counterstained with 4 0 ,6-diamino-2-phenylindole. Stained slides were analyzed under a fluorescent microscope (Olympus BX51; Olympus Optical Company, Hamburg, Germany). To detect adenoviral hexon proteins in the tumor xenografts, paraffin-embedded sections of tumors obtained at day 13 after treatment were de-paraffinized and rehydrated with xylene and ethanol according to standard procedures. Immunodetection was performed after endogenous peroxidase activity and heat antigen retrieval, using polyclonal anti-adenovirus (ab6982; Abcam Cambridge, UK) as primary antibody. Rabbit immunoglobulin G was used as control. Detection was performed using the DAKO LSAB2 system kit (DAKO, Carpinteria, CA) and slides were developed with diaminobenzidine tetrahydrochloride (DAKO) and counterstained with hematoxylin. The administration of the OCCAV-infected carrier cells into canine patients will most likely require a safeguard against the multiplication of the few cells that may escape virus-induced killing. Irradiation is an alternative treatment of choice to this end, as doses known to abolish cell multiplication were still found to allow cells to remain alive for a certain time. In canine cells, it has been shown that a radiation dose between 15 and 100 Gy is sufficient to block completely the cloning capacity of the tumor cells. 23 We confirmed that a single dose of 30 Gy on D17 and Abrams cell lines inhibited cell proliferation (data not shown). Consequently, canine cell lines were inactivated with a single dose of 30 Gy after infection and viral replication was assessed. Burst size experiments indicated that irradiated canine cell lines efficiently supported the viral replication and did not significantly affect the production of OCCAV as compared with non-irradiated cells (Figure 2) . Again, OCCAV efficiently replicated in the D17 cell line and the viral titer was significantly lower in Abrams cells. The burst size of OCCAV in irradiated D17 and Abrams cells was 750 and 54 TU per cell, respectively.
Cell-mediated delivery system efficiently carries the virus to tumor in the presence of anti-adenovirus antibodies To assess whether systemic administration of canine OSA carrier cells might effectively deliver virus to the tumor in vivo independently of the presence of Nabs or preexisting immunity, mice were passively immunized (Figure 3a) . Virus neutralization assays were performed Carrier cells to elude adenoviral Nabs F Alcayaga-Miranda et al with serum isolated from naive and pre-immunized mice at the final time point of the biodistribution experiments. Anti-Ad Nab titers following immunization reached a median value of 1:640 at 16 days post-immunization (Figure 3b ). In contrast, Nab levels were 1:20 in the nonimmunized mice. To determine the impact of a preexisting immune response in viral distribution and delivery, we compared the biodistribution of the D17-infected canine carrier cells and naked AdTL in naive animals and in those previously immunized. Luciferase expression levels were determined in liver, lung and tumor 3 days after systemic injection. As shown in Figure 3c (panel A), the pre-existing immune responses affected liver transduction in AdTL-injected mice. High levels of luciferase expression were observed in liver 72 h after i.v. administration of AdTL to naive mice. In contrast, significantly lower levels of luciferase expression were observed in livers from pre-immunized mice. This is not observed for D17-infected carrier cells: the levels of luciferase expression did not appear to change with the immune state of the mice. These effects can easily be observed in panel B, where GFP fluorescence expressed by AdTL is detected instead of luciferase; fluorescence levels in the livers of pre-immunized mice are dramatically decreased as compared with naive animals only in naked AdTL-treated mice. It has previously been reported that non-hematopoietic cells can be trapped in organs such as lung, which could explain their absence from the liver in our images. However, we did not detect significant levels of luciferase ( Figure 3 With regard to tumors, high levels of luciferase expression were observed in Abrams tumors 72 h after i.v. administration of naked AdTL to naive mice. In contrast, significantly lower levels of luciferase expression (sixfold decrease) were observed in tumors from preimmunized mice (panel E). Interestingly, the inhibition of delivery correlated with the onset of humoral immunity (Figure 3b) . However, the presence of a pre-existing immune response did not significantly affect the cellmediated delivery of AdTL.
It should be noted that, with regard to AdTL-infected carrier cells, the limiting point of viral dose is given by the maximum amount of cells that can be injected in mice. For this experiment, even though the maximum amount of cells was injected, the viral dose was still lower than those mice injected with naked AdTL; in this regard, data from naked AdTL and AdTL-infected carrier cells cannot be directly compared. However, comparison of ratios between naive and pre-immunized mice for each treatment are valid and they are shown in Table 1 . The most notable result is a 3541-fold reduction of luciferase expression in the livers of pre-immunized mice from the naked AdTL-treated group, which contrasts with data from carrier-cell-treated mice. A similar effect is observed in the tumors, albeit less dramatic (5.79-fold reduction versus 0.93-fold). In the lung, results are fairly similar for both treatments.
Cell-mediated systemic antitumoral efficacy of OCCAV-infected canine carrier cells in a canine OSA xenograft model After obtaining the biodistribution data from D17 carrier cells, we next sought to find out whether the infected carrier cells could elicit an antitumoral response in OSA-bearing mice. The purpose of this experiment was also to compare D17 and Abrams cell lines-separate and in combination-to evaluate which was the most efficient treatment to deliver OCCAV. For this experiment, BALB/c nu/nu carrying Abrams subcutaneous tumors were treated with a single i.v. injection of 5 Â 10 6 D17 or Abrams carrier cells infected with OCCAV per mouse. A mixture of both cell lines was also injected to evaluate whether an improvement in antitumoral potency could be achieved (Figure 4a ). As Figure 4b shows, animals treated with OCCAV-infected D17 carrier cells showed significantly reduced tumor growth compared with the control group (P ¼ 0.002) and to the OCCAV-infected Abrams carrier-cell group (P ¼ 0.039). Moreover, tumors in animals treated with the mix of OCCAV-infected carrier cells were significantly smaller compared with the control group (P ¼ 0.024), but this treatment did not show any benefit compared with D17-infected cells. Analysis of Abrams cells tumor sections revealed viral replication in tumors injected with canine carrier cells by immunofluorescence for adenoviral capsid protein (Figure 4c ). Carrier cells to elude adenoviral Nabs F Alcayaga-Miranda et al
Effect of CAV2 immunization in systemic antitumoral efficacy of OCCAV-infected canine carrier cells Given the effective systemic delivery achieved using carrier cells and the antitumoral activity observed through systemic administration, we compared the antitumor activity of OCCAV alone and OCCAV-infected D17 carrier cells in naive and CAV2-immunized mice. We chose D17 cells as they had proven to be the most efficient in the previous experiments. Abrams tumor cells were injected subcutaneously to generate tumors and half of
Carrier cells to elude adenoviral Nabs F Alcayaga-Miranda et al the tumor-bearing animals were immunized by intraperitonealy injection of OCCAV (2.5 Â 10 10 v.p. per mouse). Seventeen days post-immunization (day 22 of the experiment), a single systemic injection of OCCAV (5 Â 10 10 v.p. per mouse) or OCCAV-infected D17 carrier cells (2.5 Â 10 6 cells per mouse) was carried out for naive and immunized animals (Figure 5a ). The Nab levels in the different groups are shown in Figure 5b . In immunized mice, the control group had a median Nab titer of 1:80 as had the OCCAV-infected D17 carrier cells, whereas the OCCAV alone had a median Nab titer of 1:320. In naive mice, the control group Nab titer was undetectable, whereas the OCCAV alone had a median Nab titer of 1:80 and the OCCAV-infected D17 carrier cells had a median Nab titer of 1:20. Figure 5c shows the antitumoral response of carrier cells versus OCCAV alone (panel A). Growth of tumors in non-immunized (panel B) and immunized groups (panel C) that received systemic injections of naked OCCAV was not inhibited, although the growth of tumors in non-immunized mice was delayed with respect to immunized mice. In contrast, in naive animals, the tumor measurement data showed that the injection of OCCAV-infected D17 carrier cells exerted a significant antitumoral activity compared with the PBS group (P ¼ 0.002). In addition, among immunized animal groups, we observed significant suppression of tumor growth in the OCCAV-infected D17 carrier-cells group compared with the PBS group (P ¼ 0.003) and the OCCAV group (P ¼ 0.004). Therefore, the systemic cell-mediated tumor delivery and antitumoral efficacy were not affected by pre-existing anti-CAV2 antibodies. Immunohistochemistry for adenoviral capsid protein for non-immunized mice (Figure 5d, panel A) shows larger amounts of virus in cells treated with D17 carrier cells than in those treated with OCCAV alone. The same is true for immunized mice (Figure 5d, panel B) .
Discussion
An increase in the incidence of cancer in dogs is associated with longer life expectancy resulting from advances in pet nutrition and overall advances in veterinary care. Available cancer treatment options for dogs with OSA include surgical removal of the tumors, radiation therapy and chemotherapy. 2 However, these strategies often do not avoid the development of fatal distant metastatic disease 1 and consequently the development of new therapies for OSA in dogs is essential. The use of conditionally replicating adenovirus opens a new prospect to the treatment if this tumor and OCCAV, a CAV2-derived virus that contains the osteocalcin promoter restricting viral replication to dog OSA cells, are candidates that display a good profile in both selectivity and efficacy.
However, most dog patients display high levels of the pre-existing antibodies against CAV2 as a consequence of previous infections or active vaccination programs.
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Previous studies with human adenoviral vectors have shown that after systemic delivery, neutralizing antiviral antibodies represent a major obstacle in virus delivery, which impairs the oncolytic effect at the target tumor site. 24 Moreover, antiviral immunoglobulins have functions beyond virus neutralizing and are able to activate a specific innate receptor displaying cross-talk between adaptive and innate immunity. 25 Altogether, these mechanisms result in poor transduction efficiency upon re-administration, which is required to achieve significant therapeutic benefit. To circumvent pre-existing immunity, we used canine tumoral OSA cells as virus delivery vehicles capable of concealing viral antigen on its way to the tumor. Our biodistribution experiments indicate that these cells could successfully reach the tumor site and deliver an OV to tumor cells in an immunized mice model. In such a model, antiviral antibodies have been shown to intercept naked virus before it reaches the tumor and thereby reduce its effective therapeutic dose. Although we could observe similar levels of luciferase expression in tumors from mice-injected systemically with adenovirus alone with respect to tumors from mice injected with D17-infected carrier cells, the amount of particles inoculated could potentially be much higher if a replicative virus as OCCAV is used. One of the advantages of using tumor cells as carriers is that these cells can act as local viral factories allowing viral amplification of the initially inoculated dose; 16 consequently, much larger numbers of viral particles would reach the tumor tissue. Therefore, our results suggest that carrier cells can reach the target tumor site irrespectively of the presence of Nabs; this fact, coupled with the ability of carrier cells to amplify the amount of viruses that reach the tumor, would grant a clear advantage to viral-infected carrier cells as compared with virus alone.
Interestingly, the use of carrier cells also resulted in reduced adenovirus uptake by liver in mice. Absence of adenovirus from liver was not caused by entrapment of carrier cells in the lung, as has been reported for other non-hematopoietic cells. Preclinical and clinical studies have shown that the therapeutic dose of oncolytic adenoviruses is often limited by liver toxicity after intravascular delivery. 26 The stealthy passage of adenovirus-loaded cells through the liver also indicates that the use of tumor cells as carriers for oncolytic adenovirus can efficiently prevent limiting liver toxicity after systemic administration.
It should be noted that, as mentioned in the results section, biodistribution results from naked adenovirus are not directly comparable with infected carrier cells as these carry a much lower inoculum. However, the fact that infected carrier cells were still able to reach the tumor site and generate an antitumoral response (more efficiently, as will be described later) supports the use of carrier cells to improve viral delivery. We have also compared ratios rather than raw values to avoid comparing different conditions.
When using OCCAV, we observed that virus released into the tumor parenchyma by the canine OSA carrier cells was able to effectively infect and replicate in neoplastic cells inducing a significant decrease in tumor growth after systemic administration. Most importantly, the systemic antitumoral activity of the carrier cell loaded with OCCAV was evident even in the presence of circulating antibodies, which is a more relevant situation from a clinical point of view. In contrast, the injection of OCCAV alone was not effective to control tumor growth; in spite of tumor size being somewhat lower in the OCCAV-treated animals group as compared with the control group, only non-significant differences were recorded. When using a pre-immunized mice model, no antitumoral activity of naked OCCAV was observed.
The type of cells used as carriers has an important function in determining the therapy outcome. We have previously demonstrated that tumor cells can be used to target tumors. 19 OCCAV-infected D17 carrier cells displayed a much more effective antitumoral effect as compared with Abrams carrier cells in systemic injections, probably because of a higher viral burst of D17 cells (Figure 1a, panel A) than of Abrams cells (Figure 1a , panel B), which offers increased potential for dose amplification. Moreover, further confirmation that viral production in carrier cells is linked to antitumoral activity comes from the observation that the homogeneous mix of infected cells showed an intermediate therapeutic efficacy between the D17 and Abrams-infected carrier cells.
A critical control point in cell-mediated delivery systems is the in vitro loading phase. Short infection times are necessary to achieve effective immune evasion and tumor delivery avoiding progeny release before tumor targeting. Furthermore, to achieve effective immune evasion, viral antigen expression on the cell surface during the systemic delivery phase must be minimized, and consequently infection time for carrier cells must be as short as possible. 27 However, viral protein expression on the cell surface does not possess the same importance for adenoviruses as for other OVs as Nabs recognize viral proteins not expressed on the carrier-cell surface. 28 We performed short infection times as a measure of safeguard. In our studies, the loading time was set to 4 h, as this is the minimum amount of time necessary to infect a substantial proportion of carrier cells. Moreover, the viral yield kinetics of the OCCAV (Figure 1a and 2a) showed the absence of viral production and release within the first 16 h after infection.
Any therapeutic approach that involves the administration of tumor cells to cancer patients must include a safety issue regarding the residual oncogenic risk of these cells. In our protocol, we offer three safeguards against this risk through the treatment of neoplastic carrier cells. First, cells are infected with the oncolytic adenovirus at an MOI that causes their death in culture. Second, cells are irradiated with g-radiation at a dose that abolishes their proliferation in vitro. Post-infection g-irradiation appears to be the treatment of choice, because it preserves viral replication and prolongs the production and release of progeny virions while at the same time suppressing the growth of the carrier cells. [15] [16] [17] Lastly, the carrier cells are heterologous and rejected because of their immunological incompatibility.
In spite of the detrimental function of the humoral immunity in adenovirus delivery, it has also been postulated that immunogenicity of the carrier cells themselves may enhance the antitumoral response, as the activation of antitumor immunity during the virotherapy can contribute to some degree to tumor eradication. Indeed, herpes simplex virus 17 and vesicular stomatitis virus 8 appear to exert antitumoral immune responses in addition to their oncolytical effect. In a similar manner, herpes simplex virus, 17 vesicular stomatitis virus 8 and Newcastle disease virus 29 -infected tumor cells have been reported to activate antitumoral immunity. Previous studies with replication-competent adenovirus-infected carrier-cell systems have reported the use of wild-type HAd5 adenovirus-infected MDA-MG-231 cells 30 and also of granulocyte-macrophage colonystimulating factor-expressing HAd5 loaded into A549 and 293 cells. 10 In this last work, Hamada et al. 10 reported that bystander transfection was mediated by carrier-cellderived cell fragments containing viral particles that were engulfed by proliferative target cancer cells. This engulfment-mediated transfer of adenovirus was not inhibited by anti-adenovirus antibodies and enabled repetitive infection. Moreover, in this system, carrier-cell-mediated adenoviral infection produced CTL responses against target cells as well as adenoviruses. However, the unavailability of immunocompetent animal models to monitor such complex responses impairs proper interpretation of these data.
Our study provides the first evidence that systemic administration of the OV OCCAV delivered by carrier cells in canine tumors results in a significant decrease in tumor growth even in the presence of a high titer of Nabs in a canine OSA model. Our strategy is radically different from the current osteosarcoma treatment (surgery and chemotherapy) and could be used in combination. Taken together, these findings suggest that carrier-cell-mediated delivery of OCCAV has the potential to become a successful therapy in canine patients with osteosarcoma.
